Nasdaq4d
Sonnet BioTherapeutics Announces Notice of Allowance for Second Patent on Variant Interleukin-18 Binding Protein for Enhanced Cancer Therapeutics
Sonnet BioTherapeutics Holdings, Inc. announced that the United States Patent and Trademark Office has issued a Notice of Allowance for a new patent related to its modified form of Interleukin-18 ...
Nature6y
Interleukin-17 and brain injury in stroke
Japanese researchers now demonstrate for the first time that the interleukin (IL)-23–IL-17 axis is essential for brain inflammation after stroke. “Macrophages infiltrating the site produce IL ...
Nature5y
INTERLEUKIN-6 LEVELS IN NEONATAL SEPSIS
Clinical diagnosis is difficult and no reliable diagnostic test exists. Interleukin-6 (IL-6) is a central mediator of the sepsis syndrome. In this study we examined the diagnostic value of plasma ...
pharmaphorum3d
The rise and market race of anti-IL23p19 therapies in IBD: How ECCO 2025 readouts will shape the anti-interleukin landscape
In Europe, these therapies were introduced between 2006 and 2013. The anti-TNF era was followed by the emergence of interleukin (IL) inhibitors, with J&J’s Stelara (ustekinumab) leading the way ...